tiprankstipranks
Trending News
More News >
Urogen Pharma (URGN)
:URGN
US Market
Advertisement

Urogen Pharma (URGN) Earnings Dates, Call Summary & Reports

Compare
619 Followers

Earnings Data

Report Date
Nov 17, 2025
Before Open (Confirmed)
Period Ending
2025 (Q3)
Consensus EPS Forecast
-0.64
Last Year’s EPS
-0.55
Same Quarter Last Year
Based on 8 Analysts Ratings

Earnings Call Summary

Q2 2025
Earnings Call Date:Aug 07, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements, including FDA approval of ZUSDURI and strong revenue growth for JELMYTO. However, these were balanced by challenges such as reimbursement issues for ZUSDURI and increased operating expenses, resulting in a larger net loss.
Company Guidance
During the UroGen Pharma Second Quarter 2025 Earnings Call, the company announced several key metrics and guidance for the year. They reported net product revenues of $24.2 million for JELMYTO, an 11% increase over the same period in 2024. UroGen has expanded its sales team to 82 territories to support the launch of ZUSDURI, which was recently approved by the FDA for treating recurrent low-grade intermediate risk non-muscle invasive bladder cancer. The total available market for ZUSDURI exceeds $5 billion annually. The company expects to maintain a strong financial position with $161.6 million in cash and equivalents as of June 30, 2025. UroGen reiterated its guidance for full-year 2025, expecting JELMYTO revenues between $94 million and $98 million and operating expenses in the range of $215 million to $225 million. The company is optimistic about achieving sustainable growth with its two commercial products and advancing pipeline.
FDA Approval of ZUSDURI
ZUSDURI was approved for adults with recurrent low-grade intermediate risk non-muscle invasive bladder cancer, marking a significant milestone for UroGen and offering a new treatment paradigm.
Strong JELMYTO Revenue Growth
JELMYTO achieved net product revenues of $24.2 million in Q2 2025, representing an 11% increase over the same period in 2024.
Expansion of Sales Force
The sales team expanded from 50 to 82 territories to support the launch of ZUSDURI, positioning the company to reach a broader market.
Positive Clinical Data for ZUSDURI
In the pivotal Phase III ENVISION trial, 79% of patients achieved a complete response at 3 months, with a 24-month duration of response of 72.2%.
Robust Cash Position
UroGen maintains a strong balance sheet with $161.6 million in cash, cash equivalents, and marketable securities as of June 30, 2025.

Urogen Pharma (URGN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

URGN Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Nov 17, 2025
2025 (Q3)
-0.64 / -
-0.55
Aug 07, 2025
2025 (Q2)
-0.86 / -1.05
-0.91-15.38% (-0.14)
May 12, 2025
2025 (Q1)
-0.80 / -0.92
-0.975.15% (+0.05)
Mar 10, 2025
2024 (Q4)
-0.72 / -0.80
-0.72-11.11% (-0.08)
Nov 06, 2024
2024 (Q3)
-0.82 / -0.55
-0.6819.12% (+0.13)
Aug 13, 2024
2024 (Q2)
-0.83 / -0.91
-1.0311.65% (+0.12)
May 13, 2024
2024 (Q1)
-0.87 / -0.97
-1.325.38% (+0.33)
Mar 14, 2024
2023 (Q4)
-0.68 / -0.72
-1.2240.98% (+0.50)
Nov 14, 2023
2023 (Q3)
-0.85 / -0.68
-1.1339.82% (+0.45)
Aug 10, 2023
2023 (Q2)
-1.14 / -1.03
-1.1812.71% (+0.15)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

URGN Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Aug 07, 2025
$20.01$18.59-7.10%
May 12, 2025
$10.38$11.14+7.32%
Mar 10, 2025
$9.82$9.92+1.02%
Nov 06, 2024
$12.21$12.24+0.25%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Urogen Pharma (URGN) report earnings?
Urogen Pharma (URGN) is schdueled to report earning on Nov 17, 2025, Before Open (Confirmed).
    What is Urogen Pharma (URGN) earnings time?
    Urogen Pharma (URGN) earnings time is at Nov 17, 2025, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is URGN EPS forecast?
          URGN EPS forecast for the fiscal quarter 2025 (Q3) is -0.64.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis